---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301868"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:48:30.416474+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biora receives Nasdaq delisting notice for minimum bid price non-compliance

## Summary
- Nasdaq Staff notified Biora on Dec 6, 2022 that it fails to meet the minimum bid price requirement under Listing Rule 5450(a)(1).
- Company will request a hearing before the Nasdaq Hearings Panel, which will stay any further delisting action pending a decision.
- Biora filed a proxy statement on Nov 29 for a Dec 19 special meeting to authorize a reverse stock split (ratio 5:1 to 25:1) as part of a compliance plan.
- There is no immediate impact on trading of common stock (symbol BIOR) while the hearing process is ongoing.

## SEC filing metadata
- accession: 0001193125-22-301868
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/0001193125-22-301868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/d434300d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301868
- JSON: https://secwatch.observer/filing/0001193125-22-301868.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301868.txt

## Key facts
- Listing & Compliance Notices
  BIORA THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: December 6, 2022, Biora Therapeutics, Inc. (the “ Company ”) received a determination from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, due to the Company’s continued non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “ Rule ”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company plans to timely request a hearing before the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/0001193125-22-301868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.